Skip to main content

Interleukin-18: Biology and Role in the Immunotherapy of Cancer

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Interleukin-18 (IL-18) is an immunostimulatory cytokine belonging to the IL-1 family. IL-18 can regulate both innate and adaptive immune responses through its effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B cells. IL-18 acts synergistically with other pro-inflammatory cytokines to promote interferon-γ (IFN-γ) production by NK cells, T cells, and possibly other cell types. Systemic administration of IL-18 has been shown to have significant antitumor activity in several preclinical animal models. Phase I clinical trials of recombinant human IL-18 have demonstrated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include activation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo. A phase II study of IL-18 in patients with metastatic melanoma confirmed its safety but suggested limited efficacy of IL-18 monotherapy in this setting. IL-18 appears to act predominantly as a costimulatory cytokine and its optimal use for cancer immunotherapy may be in combination with other immunostimulatory cytokines, vaccines, or monoclonal antibodies.







Keywords: CD4+ T cells; CLINICAL TRIALS; Chemotherapy; Cytokine; Gene Therapy; ICAM-1; IL-1 family; IRAK; Interleukin-18; MCA205; Melanoma; MyD88; Rituximab; STAT; Stem Cell Transplantation; T cell; TRAF6; VCAM-1; adenovirus; antibodies; carcinogenesis; chemotherapeutic agents; endothelial cells; fibroblasts; immunotherapy; interferon-γ; interleukin-12; monoclonal antibodies; monocytes; natural killer cell; prostate specific antigen; rituximab; vaccines

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986710793176348

Publication date: October 1, 2010

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2010/00000017/00000029/art00008
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more